Scholarlink

Background <p>Combination therapy with immune checkpoint inhibitors (ICIs) and cytotoxic or targeted anticancer agents has improved survival in multiple cancers but may exacerbate drug-related skin toxicities.&#xa0;These toxicities share inflammatory mechanisms, and ICI-induced immune cell infiltration into the skin may increase both their incidence and severity. This review evaluated the impact of adding ICIs on skin toxicities in adult Asian patients<b>.</b></p> Methods <p>PubMed was searched for English-language clinical trials published between January 2014 and September 2025 using the keywords “immune checkpoint inhibitor” and “clinical study.” Randomized controlled trials involving adult Asian patients treated with ICIs in combination with cytotoxic chemotherapy or molecularly targeted therapy were included.</p> Results <p>Of 7287 identified articles, 28 met inclusion criteria. Studies assessed capecitabine-induced hand–foot syndrome (HFS), multikinase inhibitor–induced hand–foot skin reaction (HFSR), taxane-induced alopecia, and epidermal growth factor receptor (EGFR) inhibitor-related skin toxicities. The incidence of capecitabine-related HFS (11/13 articles) and EGFR inhibitor-related skin toxicities (1/1 article) tended to be higher with the addition of ICIs.</p> Conclusions <p>While ICIs have substantially improved survival outcomes, their immunomodulatory effects may amplify drug-specific dermatologic toxicities when used in combination regimens. Shared inflammatory pathways and immune cell recruitment to the skin likely underlie this interaction, underscoring the importance of anticipatory monitoring and optimized management strategies in combination therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月16日

查看全文
  • Yohei Iimura,
  • Junichi Higuchi,
  • Akimitsu Maeda,
  • Kazuhiro Shimomura,
  • Hirotoshi Iihara,
  • Hironori Fujii,
  • Takuya Iwamoto,
  • Yoshitaka Saito,
  • Hisanaga Nomura,
  • Keiko Komori,
  • Hidenori Tokuda,
  • Ryuta Urakawa,
  • Tatsuya Sumiya,
  • Ryosuke Yanai,
  • Mariko Kono,
  • Masaki Ihira,
  • Tomohiro Kurokawa,
  • Yuya Ishii,
  • Masanobu Uchiyama,
  • Teppei Yamada,
  • Yasumasa Tsuda,
  • Yusuke Tsuchiya,
  • Toshinobu Hayashi,
  • Seiichiro Kuroda

摘要

Background

Combination therapy with immune checkpoint inhibitors (ICIs) and cytotoxic or targeted anticancer agents has improved survival in multiple cancers but may exacerbate drug-related skin toxicities. These toxicities share inflammatory mechanisms, and ICI-induced immune cell infiltration into the skin may increase both their incidence and severity. This review evaluated the impact of adding ICIs on skin toxicities in adult Asian patients.

Methods

PubMed was searched for English-language clinical trials published between January 2014 and September 2025 using the keywords “immune checkpoint inhibitor” and “clinical study.” Randomized controlled trials involving adult Asian patients treated with ICIs in combination with cytotoxic chemotherapy or molecularly targeted therapy were included.

Results

Of 7287 identified articles, 28 met inclusion criteria. Studies assessed capecitabine-induced hand–foot syndrome (HFS), multikinase inhibitor–induced hand–foot skin reaction (HFSR), taxane-induced alopecia, and epidermal growth factor receptor (EGFR) inhibitor-related skin toxicities. The incidence of capecitabine-related HFS (11/13 articles) and EGFR inhibitor-related skin toxicities (1/1 article) tended to be higher with the addition of ICIs.

Conclusions

While ICIs have substantially improved survival outcomes, their immunomodulatory effects may amplify drug-specific dermatologic toxicities when used in combination regimens. Shared inflammatory pathways and immune cell recruitment to the skin likely underlie this interaction, underscoring the importance of anticipatory monitoring and optimized management strategies in combination therapy.